Finvest
DXCM Medical Devices · CGM · Diabetes tech · Recurring revenue · Thesis updated July 12, 2026

Dexcom sensor growth is repairing margins

01 Running thesis

The margin fix is the test

Dexcom has a strong setup: more people are using continuous glucose monitors, and most sales come from sensors that customers replace again and again. That gives the company a repeat-sales model, not a one-time device sale.

The thesis improved after Q1 2026. Gross margin reached 62.9%, up from 56.9% in Q1 2025, and management guided full-year non-GAAP gross margin to 63% to 64%. That matters because earlier results had been hurt by manufacturing problems, lower yields, replacement costs, and freight pressure.

Growth also has a new lane. Dexcom is pushing into adults with Type 2 diabetes who do not use insulin, helped by Stelo and a Prime Therapeutics partnership that is expected to lift covered lives in that group to more than 7 million by the end of 2026.

The bear case is no longer only about whether the factory can improve. It is now about whether outside costs and policy can take away the gains. Medicare reimbursement is expected to fall beginning in 2028, and management has warned that fuel prices and shipping routes could pressure cost of goods sold.

Apr 2026▲Management guided full-year non-GAAP gross margin to 63% to 64% and raised operating margin guidance to 23% to 23.5%. That made the Q1 margin rebound look more durable.
Apr 2026▲The Q1 2026 10-Q showed gross margin rose to 62.9% from 56.9% a year earlier. Management tied the gain to higher sales volume, better manufacturing efficiency, higher production volume, and better fixed-cost absorption.
Feb 2026▼The FY2025 10-K confirmed that Medicare reimbursement is expected to fall beginning in 2028 after CMS added CGMs to competitive bidding. It also kept the March 2025 FDA warning letter as an unresolved risk.
Oct 2025▲Q3 2025 revenue growth re-accelerated to 22% year over year, and gross margin expanded to 60.5% from 59.7%. That was the first clear sign that the operational reset might be working.
Jul 2025▼The Q2 2025 filing showed continued gross margin pressure and introduced a proposed CMS competitive bidding risk for CGMs. Disposable sensors still improved to about 97% of revenue.
May 2025▼The Q1 2025 filing disclosed an FDA warning letter tied to manufacturing and quality systems. Gross margin fell to 56.9%, raising the execution risk.
Feb 2025▼The FY2024 10-K showed revenue grew 11% to $4.03 billion, but gross margin fell from 63.2% to 60.5%. Management cited pricing headwinds, freight costs, inventory charges, and G7 manufacturing challenges.
Oct 2024→The initial thesis framed Dexcom as a CGM leader with a repeat sensor model. The launch of Stelo added a new growth option, while slower U.S. growth and margin pressure kept the view balanced.
02 Business model

Sensors drive repeat sales

Dexcom makes continuous glucose monitoring systems, called CGMs. A CGM uses a small sensor on the body to track glucose through the day and send readings to a phone, receiver, insulin pump, or health app.

The money comes mostly from disposable sensors. In the June 2025 quarter, disposable sensor and other revenue was about 97% of total revenue, while reusable hardware was about 3%. This is like a razor-and-blade model: the device ecosystem matters, but the repeat sensor sale is the core.

Demand depends on doctors, insurers, pharmacies, distributors, and patient habit. Better coverage can open new groups of users. Worse reimbursement can cut price, even if unit demand stays healthy.

The model breaks if Dexcom cannot make high-quality sensors at scale, if coverage weakens, or if rivals take share with cheaper or easier systems. The current thesis gives credit for better manufacturing efficiency, but keeps the FDA warning letter and future CMS pricing cuts in view.

03 Product portfolio

From insulin users to metabolic health

Growth engine

Dexcom G7

G7 is the main newer CGM system for intensive diabetes management. Dexcom is rolling out a 15-day version for adults in the U.S., with a target of converting nearly 50% of its user base by year-end 2026.

Cash cow

Dexcom G6

G6 is the older integrated CGM platform launched before G7. It still supports the installed base and helps keep patients inside Dexcom's ecosystem.

Option

Stelo

Stelo is Dexcom's over-the-counter glucose biosensor for adults with prediabetes and Type 2 diabetes who do not use insulin. It opens a larger metabolic health market, but adoption and payer support are still being proven.

Steady

Reusable hardware

Receivers and related reusable hardware are a small part of revenue. In the June 2025 quarter, reusable hardware was about 3% of total revenue.

Steady

Open device and app connections

Dexcom builds platforms that can connect with insulin pumps and digital health apps. These links can make the sensor more useful and harder to replace.

04 Business segments

Mostly U.S., still global

United States72%modest
International28%growing fast

The geographic mix is from the twelve months ended December 31, 2025. The United States was 72% of revenue and international markets were 28%, so U.S. reimbursement and access remain major drivers.

05 Risk factors

What could break the story

Margin targets miss

High impact · Medium odds

Dexcom's Q1 2026 margin rebound is central to the bull case. Management guided full-year non-GAAP gross margin to 63% to 64%, which signals confidence in better manufacturing. If shipping, fuel, mix, or factory issues pull results below that range, the recovery story weakens.

We watchQuarterly gross margin versus the 63% to 64% full-year non-GAAP guide.

CMS pricing cut in 2028

High impact · High odds

CMS extended the DMEPOS competitive bidding program to include CGMs and receivers, with contracting in 2027 and payment changes effective January 1, 2028. Dexcom says Medicare reimbursement for its CGM systems is expected to decrease beginning in 2028. That could pressure revenue per user and profit per sensor.

We watchFinal CMS bid terms, 2027 contracting updates, and management comments on Medicare price impact.

FDA warning letter remains open

High impact · Medium odds

Dexcom received an FDA warning letter in March 2025 tied to manufacturing processes and its quality management system. The company has submitted responses, but the matter is not yet resolved to the FDA's satisfaction. The filing says the letter does not currently block production, sales, distribution, or new 510(k) submissions, but failure to satisfy the FDA could lead to tougher actions.

We watchCompany disclosure that the FDA warning letter has been resolved or that new limits have been placed on Dexcom.

Type 2 non-insulin adoption stalls

Medium impact · Medium odds

Stelo and payer deals give Dexcom a path into adults with Type 2 diabetes who do not use insulin. That market could be large, but the use case is newer than intensive insulin management. If consumers do not keep using the product, or payers limit support, growth could slow.

We watchStelo user trends, payer coverage updates, and progress toward more than 7 million covered Type 2 non-insulin lives by the end of 2026.

G7 15-day conversion falls short

Medium impact · Medium odds

The G7 15-day sensor can help Dexcom improve convenience and defend share. Management is targeting conversion of nearly 50% of the user base to this model by year-end 2026. A slow switch could signal weaker patient uptake, supply limits, or competitive pressure.

We watchManagement updates on the nearly 50% user base conversion target for the G7 15-day sensor.
06 Quick answers

In one breath

How does Dexcom make money?

Dexcom sells CGM systems, but most revenue comes from disposable sensors that users replace over time. In the June 2025 quarter, disposable sensor and other revenue was about 97% of total revenue.

Why do margins matter so much for Dexcom?

Dexcom had been hurt by manufacturing inefficiencies, freight costs, lower yields, and replacement costs. Q1 2026 showed improvement, and management guided full-year non-GAAP gross margin to 63% to 64%, so investors are watching if the fix lasts.

What is Stelo?

Stelo is Dexcom's over-the-counter glucose biosensor for adults with prediabetes and Type 2 diabetes who do not use insulin. It is meant to expand Dexcom beyond its core intensive diabetes management market.

What is the biggest long-term policy risk?

CMS added CGMs and receivers to the DMEPOS competitive bidding program. Dexcom expects Medicare reimbursement for its CGM systems to decrease beginning in 2028.